Pular para o conteúdo principal
Ranking Invest

DVAX - Dynavax Technologies Corporation

Segmento: HealthcareDynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Análise Ranking Invest

Valuation estimado
$ 758.16 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 530.94 Mi

Dívida Líquida

$ 234.31 Mi

L4T

-$ 60.07 Mi

MM4T

-23.49%

Indicadores Básicos

ROE

-11.31%

Índices de Previsibilidade

Receita Líquida

F0.38

Lucro

G11.54

Margem

E1.69

Índices de Tendência

Receita Líquida

E-5.56

Lucro

F-5.62

Margem

E-1.98

Índices de Endividamento

DIV/PAT

0.44

DIV/L4T

-3.90

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.